Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 in Boston. Company executives will participate in a fireside chat at 3:10 pm ET and hold investor meetings that day. A webcast will be available beginning at 3:10 pm ET and posted on the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – KRYS
In the Feb 24 session, KRYS declined 2.80%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Earnings results | Positive | +4.1% | Strong Q4 and FY2025 results with high-margin VYJUVEK revenue and cash build. |
| Feb 10 | Earnings date set | Neutral | -0.7% | Scheduled Q4 and FY2025 earnings release and business update webcast. |
| Feb 09 | Regulatory designation | Positive | -0.1% | FDA RMAT designation for KB707 in advanced or metastatic NSCLC. |
| Jan 08 | Clinical data update | Positive | +1.0% | Positive interim KB407 Phase 1 CORAL-1 data in cystic fibrosis patients. |
| Jan 07 | Clinical call scheduled | Neutral | -1.2% | Announcement of Jan 8 investor call to share interim CORAL-1 KB407 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive fundamental or clinical updates have often coincided with modest positive moves, while regulatory designations have seen muted or slightly negative reactions.
Over recent months, KRYS has reported several notable milestones. On Feb 17, strong 4Q and FY2025 earnings with $389.1M product revenue and high gross margins were followed by a 4.12% gain. Earlier, an RMAT designation for KB707 in NSCLC on Feb 9 saw a flat reaction, and positive KB407 Phase 1 data on Jan 8 produced a modest 1.03% rise. Earnings-date and event-preview announcements showed small mixed moves, indicating investors respond more to concrete results than scheduling news like today’s conference appearance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
